Pharmacological Management of Hereditary Angioedema with C1-Inhibitor Deficiency in Pediatric Patients

Research output: Review article

6 Citations (Scopus)

Abstract

Hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) is a form of bradykinin-mediated angioedema. It is a rare disorder with an onset during childhood in most instances. Therefore, familiarity with the options for the management of pediatric cases is indispensable. The recurrent angioedematous episodes do not respond to conventional treatments and may evolve into a life-threatening condition. In view of the recommendations adopted by international consensus in 2016, patient management and follow-up should be guided by an individualized strategy. During the last decade, various medicinal products with novel modes of action and different posology have been developed for the treatment of C1-INH-HAE. These drugs either inhibit the release of bradykinin (plasma-derived C1-inhibitors, recombinant C1-inhibitors, kallikrein inhibitors) or prevent the released bradykinin from binding to its receptor (bradykinin B2 receptor antagonists). This review summarizes the properties of the medicinal products currently available for the treatment of C1-INH-HAE, the indications for their use in pediatric patients, and the findings of the clinical trials conducted in this patient population. It is concluded by a brief outline of future therapeutic options.

Original languageEnglish
Pages (from-to)135-151
Number of pages17
JournalPediatric Drugs
Volume20
Issue number2
DOIs
Publication statusPublished - ápr. 1 2018

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Pharmacological Management of Hereditary Angioedema with C1-Inhibitor Deficiency in Pediatric Patients'. Together they form a unique fingerprint.

  • Cite this